Objective: To assess the economic impact of providing real time continuous glucose monitoring (CGM) for people with type 1
diabetes (T1D) and impaired awareness of hypoglycaemia (IAH) within North West (NW) London clinical commissioning groups
(CCGs). Methods: The eligible population for CGM and inputs for the economic budget impact model developed were derived from
published data. The model includes cost of CGM; cost savings associated with lower hypoglycaemia related hospital admissions, accidents
and emergency visits; self-monitoring of blood glucose (SMBG) strip usage; and glycated haemoglobin (HbA1c) reduction-related avoided
complications and insulin pump use. Results: The cost of CGM for T1D-IAH (n=3,036) in the first year is £10,770,671 and in the fourth year is
£11,329,095. The combined cost off-sets related to reduced hypoglycaemia admissions, SMBG strip usage and complications are £8,116,912
and £8,741,026 in years one and four, respectively. The net budget impact within the NW London CCGs is £2,653,760; £2,588,068 in years one
and four respectively. Conclusions: Introduction of CGM for T1D-IAH patients will have a minimal budget impact on NW London CCGs, driven
by cost of CGM and offsets from lower hypoglycaemia-related costs, reduced SMBG strip usage, avoided HbA1c-related complications and
lower insulin pump use.
Continuous glucose monitoring, economics,
type 1 diabetes, clinical commissioning group
Shraddha Chaugule is an employee
of Dexcom, Inc. Brigitte Klinkenbijl is an employee
of Dexcom, Inc. and owns stock in the company.
Claudia Graham is an employee of Dexcom, Inc.
and owns stock in the company. Nick Oliver has
nothing to declare in relation to this article.
This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.